RxDoctor Payments Data

Steven Ledesma, MD

Nephrology · Oxnard, CANPI 1386718799

Payments from drug & device makers

$235in general payments, 2019–2025

Across 7 payments — averaging $33.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$122
  • Nxstage Medical, Inc.$44
  • Fresenius USA Marketing, Inc.$24
  • AstraZeneca$23
  • Akebia Therapeutics Inc$22

What the payments were for

  • Food & beverage$11348%
  • Education$12252%

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$235 in reported general payments places this provider in the 20th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$424,043
Medicare patients
545
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate145$42,585
VelphoroSucroferric Oxyhydroxide13$26,773
FarxigaDapagliflozin Propanediol19$18,523
VeltassaPatiromer Calcium Sorbitex14$14,168
Calcium Acetate43$3,127
Hydralazine Hcl178$2,801
Valsartan142$2,612
Sodium Polystyrene Sulfonate37$2,576
Mycophenolic AcidMycophenolate Sodium12$2,462
RetacritEpoetin Alfa-Epbx16$2,421
Tacrolimus11$1,737
Candesartan Cilexetil22$1,651
Furosemide237$1,364
Labetalol Hcl25$1,300
Bumetanide36$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$24$26,77313 claims
AstraZenecaFarxiga$23$18,52319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,341 nephrology providers in California.

Other nephrology in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →